voretigene neparvovec voretigene neparvovec voretigene neparvovec, sold under the brand name luxturna, is a gene therapy medication for the treatment of leber congenital amaurosis. voretigene neparvovecgene therapytarget generpe65vectoradeno-associated virus serotype 2nucleic acid typednaclinical datatrade namesluxturnaother namesvoretigene neparvovec-rzylahfs/drugs.comprofessional drug factslicense data eu ema: by inn us dailymed: voretigene_neparvovec us fda: luxturna pregnancycategory au: b2 routes ofadministrationsubretinal injectionatc codes01xa27 (who) legal statuslegal status au: s4 (prescription only) ca: rx-only / schedule d us: ℞-only eu: rx-only identifierscas number1646819-03-5drugbankdb13932unii2spi046ikdkeggd11008 leber's congenital amaurosis, or biallelic rpe65-mediated inherited retinal disease, is an inherited disorder causing progressive blindness. voretigene is the first treatment available for this condition. the gene therapy is not a cure for the condition, but substantially improves vision in those treated. it is given as a subretinal injection. voretigene neparvovec was approved for medical use in the united states in december 2017, australia in august 2020 and in canada, in october 2020. it is the first in vivo gene therapy approved by the us food and drug administration (fda). medical uses voretigene neparvovec is indicated for the treatment of people with vision loss due to inherited retinal dystrophy caused by confirmed biallelic rpe65 mutations and who have sufficient viable retinal cells. chemistry and production voretigene neparvovec is an aav2 vector containing human rpe65 cdna with a modified kozak sequence. the virus is grown in hek 293 cells and purified for administration. history it was developed by spark therapeutics and children's hospital of philadelphia. it was granted orphan drug designation for leber congenital amaurosis and retinitis pigmentosa. a biologics license application was submitted to the us food and drug administration (fda) in july 2017 with priority review. phase iii clinical trial results were published in august 2017. on 12 october 2017, a key advisory panel to the fda, composed of 16 experts, unanimously recommended approval of the treatment. the fda approved the drug on in december 2017. with the approval, spark therapeutics received a pediatric disease priority review voucher. the first commercial sale of voretigene neparvovec, which was also the first sale of any gene therapy product in the united states, occurred in march 2018. the price of the treatment at the time was announced as being $425,000 per eye.